All In MedTech

Device Trial Radar · NCT05174780

Myopia Control With a Innovative Spectacle Lens

Clinical Evaluation of A Innovative Spectacle Lens in Slowing Myopia Progression

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Dec 29, 2021

Primary completion

Oct 20, 2025

Study completion Oct 20, 2025

Sponsor

Lead sponsor
Essilor InternationalNot on our public-company list
Sponsor type
Industry
First posted
Jan 3, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that the test spectacle lens is safe and effective in slowing myopia progression in children.

Conditions

  • Myopia

Interventions

  • innovative myopia control spectacle lensDevice

    using a innovative spectacle lens to control myopia progression

  • Single vision spectacle lensDevice

    single vision spectacle lens for myopia and astigmatism correction

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Axial lengthTime frame: 36 Months
  2. Cycloplegic spherical equivalent refractionTime frame: 36 Months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Scripps Poway Optometry

    San Diego, California

  • Sabal Eye Care

    Longwood, Florida

  • Illinois College of Optometry

    Chicago, Illinois

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.